IBD: Intestinal ultrasound assessment of intestinal behavior predicts early response to anti-TNF therapy in patients with Crohn's disease

Anti-tumor necrosis factor (TNF)-α drugs, such as infliximab, are widely used to treat CD patients, especially those with frequent relapses, severe disease activity, and poor prognosis
.

However, up to 40% of patients do not respond to anti-TNF-α drugs, and about 10% have adverse drug reactions that interfere with treatment

Anti-tumor necrosis factor (TNF)-α drugs, such as infliximab, are widely used to treat CD patients, especially those with frequent relapses, severe disease activity, and poor prognosis

 

We included patients with ileal or ileocolonic CD who received anti-TNF therapy
.

All patients underwent bowel ultrasonography at baseline and at weeks 2, 6, and 14

 

Twenty of the 30 patients included in this study responded to anti-TNF therapy at week 14
.

Compared with the non-responder group, the intestinal wall thickness and SWE value of the responder group showed a significant downward trend (P = 0.

Figure: B-ultrasound showing intestinal lesions

 

This study conclusively demonstrated that changes in intestinal ultrasound behavior can be assessed as early as 2 weeks after initiation of anti-TNF therapy, and that early response to anti-TNF therapy can be predicted by intestinal ultrasound and elastography
.

This study conclusively demonstrated that changes in intestinal ultrasound behavior can be assessed as early as 2 weeks after initiation of anti-TNF therapy, and that early response to anti-TNF therapy can be predicted by intestinal ultrasound and elastography
.

Original source:

Yu-Jun Chen.

Longitudinal Bowel Behavior Assessed by Bowel Ultrasound to Predict Early Response to Anti-TNF Therapy in Patients with Crohn's Disease: A Pilot Study.
Leave a Comment here